Evolving Treatment Strategies in the Management of Ovarian Cancer: Expert Perspectives in PARP Inhibition

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from AstraZeneca

Ovarian cancer has a poor prognosis as it is usually discovered the late stages of 3 and 4, which means the cancer has already spread or metastasized to other organs. This is due in large part to the lack of symptoms during early stages of development. The 5-year survival rate for patients with ovarian cancer is approximately 45%, however new therapies and guidelines are drastically changing the treatment paradigm. Novel therapies for all types of cancers have exploded in the past 3 years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Current treatments leading the way are include poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in ovarian cancer include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.

Upon Completion of this activity, participants will be able to:

  • Examine key clinical data, including efficacy and safety, on PARP inhibitors in the management of ovarian cancer

  • Review the rationale of PARP inhibition in ovarian cancer patients who have been previously treated with several chemotherapy regimens

  • Explore recent clinical data on the use of PARP inhibitors as maintenance therapy in the management of ovarian cancer

  • Assess the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition, including those with BRCA-mutated disease

  • Describe effective strategies to proactively plan for and manage treatment-related toxicities associated with PARP inhibitors in the setting of ovarian cancer

  • Apply methods to enable optimal cost management of PARP inhibitors to be realized by multiple ovarian cancer stakeholders including managed care organizations

Faculty: Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director
Medical Gynecology and Oncology
Massachusetts General Hospital


Dr. Penson serves on an advisory board to AbbVie, Amgen, AstraZeneca, Clovis, Eisai, Genentech/Roche, Tesaro and Vascular Biogenics. He receives research support from AstraZeneca and serves on the Data Safety Monitoring Board (DSMB) for AbbVie. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue